Dermal flurbiprofen nanosuspensions: Optimization with design of experiment approach and in vitro evaluation

Ayse N Oktay,Alptug Karakucuk,Sibel Ilbasmis-Tamer,Nevin Celebi,Ayse N. Oktay
DOI: https://doi.org/10.1016/j.ejps.2018.07.009
IF: 5.112
2018-09-01
European Journal of Pharmaceutical Sciences
Abstract:Flurbiprofen (FB) is the one of the non-steroidal anti-inflammatory drugs (NSAIDs) which has low water solubility and dissolution. Nanosuspensions are promising drug delivery systems consisting pure drug particles to overcome poor water solubility issues. Recently, design of experiment (DoE) approaches have often been used to develop new formulations include nanosuspensions. The main objective of this study was to prepare FB nanosuspensions in existence of Plantacare 2000 (PL) as stabilizer using DoE approach to evaluate the critical formulation attributes (CFAs) and critical process parameters (CPPs). Particle size, particle size distribution and zeta potential values were selected as dependent variables and FB%, FB: PL and homogenization cycles were independent variables. Both 23 and 33 factorial designs were used to achieve optimum nanosuspension formulation. The final nanosuspension was freeze-dried and then crystalline state, morphological and thermal properties were investigated using X-ray diffraction, scanning electron microscopy and differential scanning calorimetry, respectively. The saturation solubility studies of nanosuspensions were conducted in comparison with the coarse powder and the physical mixture. The in vitro permeation of nanosuspension and FB solution were determined through dialysis membrane and rat skin. The particle size, polydispersity index and zeta potential values were found to range 665 nm-700 nm, 0.200-0.300 and approximately -30 mV, respectively. Nanosuspensions were obtained with spherical shape and no polymorphic or crystalline state change were observed. The saturation solubility of FB was 5.3 fold increased in nanosuspension formulation. Permeability of FB nanosuspension was higher than FB solution in rat skin. It was concluded that the DoE approach is a useful tool to prepare FB nanosuspensions and nanosuspensions benefit to improve water solubility and dermal permeation of Biopharmaceutical Classification System (BCS) Class II drugs.
pharmacology & pharmacy
What problem does this paper attempt to address?
This paper aims to solve the problem of low skin permeability and bioavailability of the non - steroidal anti - inflammatory drug flurbiprofen (FB) due to its low water solubility. By using the nanosuspension technology and combining the Design of Experiment (DoE) method to optimize the Critical Formulation Attributes (CFAs) and Critical Process Parameters (CPPs), the researchers hope to improve the solubility and skin permeability of FB, thereby improving the local or systemic therapeutic effects of the drug. Specifically, the research objectives include: 1. **Preparation of FB nanosuspension**: Prepare FB nanosuspension using microfluidization technology and use Plantacare 2000 (PL) as a stabilizer. 2. **Optimization of formulation and process parameters**: Evaluate and optimize the influence of key formulation attributes (such as FB percentage, FB:PL ratio) and key process parameters (such as the number of homogenization cycles, homogenization pressure) on the performance of nanosuspension through 2³ and 3³ factorial design experiments. 3. **Characterization of nanosuspension**: Characterize the physical properties of nanosuspension by parameters such as particle size (PS), polydispersity index (PDI) and ζ - potential (ZP), and further analyze its morphology and crystalline state using scanning electron microscope (SEM), differential scanning calorimetry (DSC) and X - ray powder diffraction (XRD). 4. **Evaluation of stability and solubility**: Conduct short - term stability tests and saturated solubility studies to verify the stability and solubility improvement effects of nanosuspension. 5. **In vitro permeation study**: Conduct in vitro permeation experiments through dialysis membrane and rat skin to evaluate the skin permeation performance of FB nanosuspension relative to FB solution. Through these studies, the authors hope to prove the effectiveness of the DoE method in optimizing the FB nanosuspension formulation and show the potential of nanosuspension technology in improving the water solubility and skin permeability of BCS II drugs.